Death by design: Where curcumin sensitizes drug-resistant tumours

Anticancer Research

Volumn 32, Issue 7, 2012, Pages 2567-2584

  Saha, Shilpi ^a   Adhikary, Arghya ^a   Bhattacharyya, Pushpak ^a   Das, Tanya ^a   Sa, Gaurisankar ^a  

^a BOSE INSTITUTE   (India)

Author keywords

Curcumin; Drug efflux pumps; Multidrug resistance; NFkappa; B; P300; P53; Review

Indexed keywords

ABC TRANSPORTER; ANTINEOPLASTIC AGENT; BREAST CANCER RESISTANCE PROTEIN; CURCUMIN; CYCLOPHOSPHAMIDE; CYTOKINE; GLYCOPROTEIN P; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MULTIDRUG RESISTANCE PROTEIN; PROTEIN KINASE B;

APOPTOSIS; CANCER CELL; CANCER STEM CELL; CELL SURVIVAL; CHEMOSENSITIVITY; CHEMOSENSITIZATION; DATA BASE; DNA DAMAGE; DNA REPAIR; DRUG CYTOTOXICITY; DRUG DETOXIFICATION; DRUG TARGETING; GENE OVEREXPRESSION; HUMAN; MULTIDRUG RESISTANCE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; REVIEW;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CURCUMIN; DRUG RESISTANCE, NEOPLASM; HUMANS; NEOPLASMS;

EID: 84865676037     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (163)

1. Sosin MD and Handa SI: Spontaneous remission of large granular lymphocytic leukaemia. Int J Clin Pract 57: 551-552, 2003. (Pubitemid 36974901)
2. Pommier Y, Sordet O, Antony S, Hayward RL and Kohn KW: Apoptosis defects and chemotherapy resistance: molecular interaction maps and networks. Oncogene 23: 2934-2949, 2004. (Pubitemid 38638854)
3. Pluen A, Boucher Y, Ramanujan S, McKee TD, Gohongi T, di Tomaso E, Brown EB, Izumi Y, Campbell RB, Berk DA and Jain RK: Role of tumor-host interactions in interstitial diffusion of macromolecules: cranial vs. subcutaneous tumors. Proc Natl Acad Sci USA 98: 4628-4633, 2001. (Pubitemid 32295027)
4. Diaconu CC, Szathmari M, Keri G and Venetianer A: Apoptosis is induced in both drug-sensitive and multidrug-resistant hepatoma cells by somatostatin analogue TT-232. Br J Cancer 80: 1197-1203, 1999. (Pubitemid 29264080)
5. Dalton WS and Jove R: Drug resistance in multiple myeloma: approaches to circumvention. Semin Oncol 26: 23-27, 1999. (Pubitemid 29483268)
6. Mohanty S, Adhikary A, Chakrabarty S, Sa G and Das T: Operation 'p53 Hunt' to combat cancer: theaflavins in action. Front Biosci (Schol Ed) 4: 300-320, 2012.
7. Gopalakrishna R and Jaken S: Protein kinase C signaling and oxidative stress. Free Radic Biol Med 28: 1349-1361, 2000. (Pubitemid 30621479)
8. Bhimani RS, Troll W, Grunberger D and Frenkel K: Inhibition of oxidative stress in HeLa cells by chemopreventive agents. Cancer Res 53: 4528-4533, 1993. (Pubitemid 23304375)
9. Bhattacharyya A, Mandal D, Lahiry L, Bhattacharyya S, Chattopadhyay S, Ghosh UK, Sa G and Das T: Black tea-induced amelioration of hepatic oxidative stress through antioxidative activity in EAC-bearing mice. J Environ Pathol Toxicol Oncol 26: 245-254, 2007.
10. Ray PK, Das T, Sa G, Ghosh AK and Chattopadhyay S: Protection of apoptotic cell death by protein A. Apoptosis 5: 509-514, 2000. (Pubitemid 32182548)
11. Sa G and Das T: Anticancer effects of curcumin: cycle of life and death. Cell Div 3: 14, 2008.
12. Sosin M and Handa S: Low dose methotrexate and bone marrow suppression. Bmj 326: 266-267, 2003. (Pubitemid 36169595)
13. Rayman P, Wesa AK, Richmond AL, Das T, Biswas K, Raval G, Storkus WJ, Tannenbaum C, Novick A, Bukowski R and Finke J: Effect of renal cell carcinomas on the development of type 1 T-cell responses. Clin Cancer Res 10: 6360S-6366S, 2004. (Pubitemid 39287492)
14. Hossain DM, Bhattacharyya S, Das T and Sa G: Curcumin: the multi-targeted therapy for cancer regression. Front Biosci (Schol Ed) 4: 335-355, 2012.
15. Koty PP, Zhang H and Levitt ML: Antisense BCL-2 treatment increases programmed cell death in non-small cell lung cancer cell lines. Lung Cancer 23: 115-127, 1999. (Pubitemid 29123881)
16. Nilsen H and Krokan HE: Base excision repair in a network of defence and tolerance. Carcinogenesis 22: 987-998, 2001. (Pubitemid 32633596)
17. Persidis A: Cancer multidrug resistance. Nat Biotechnol 17: 94-95, 1999.
18. Nooter K and Stoter G: Molecular mechanisms of multidrug resistance in cancer chemotherapy. Pathol Res Pract 192: 768-780, 1996. (Pubitemid 26302251)
19. Dean M, Hamon Y and Chimini G: The human ATP-binding cassette (ABC) transporter superfamily. J Lipid Res 42: 1007-1017, 2001. (Pubitemid 32645780)
20. Juliano RL and Ling V: A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta 455: 152-162, 1976.
21. Shain KH and Dalton WS: Cell adhesion is a key determinant in de novo multidrug resistance (MDR): new targets for the prevention of acquired MDR. Mol Cancer Ther 1: 69-78, 2001.
22. Huang CC, Wu MC, Xu GW, Li DZ, Cheng H, Tu ZX, Jiang HQ and Gu JR: Overexpression of the MDR1 gene and Pglycoprotein in human hepatocellular carcinoma. J Natl Cancer Inst 84: 262-264, 1992.
23. Kramer R, Weber TK, Morse B, Arceci R, Staniunas R, Steele G Jr. and Summerhayes IC: Constitutive expression of multidrug resistance in human colorectal tumours and cell lines. Br J Cancer 67: 959-968, 1993. (Pubitemid 23147486)
24. Petrini M, Di Simone D, Favati A, Mattii L, Valentini P and Grassi B: GST-pi and P-170 co-expression in multiple myeloma. Br J Haematol 90: 393-397, 1995.
25. Grundy M, Seedhouse C, Russell NH and Pallis M: PGlycoprotein and breast cancer resistance protein in acute myeloid leukaemia cells treated with the aurora-B kinase inhibitor barasertib-hQPA. BMC Cancer 11: 254, 2011.
26. Szakacs G, Varadi A, Ozvegy-Laczka C and Sarkadi B: The role of ABC transporters in drug absorption, distribution, metabolism, excretion and toxicity (ADME-Tox). Drug Discov Today 13: 379-393, 2008.
27. Laberge RM, Karwatsky J, Lincoln MC, Leimanis ML and Georges E: Modulation of GSH levels in ABCC1 expressing tumor cells triggers apoptosis through oxidative stress. Biochem Pharmacol 73: 1727-1737, 2007. (Pubitemid 46601409)
28. Sharom FJ: ABC multidrug transporters: structure, function and role in chemoresistance. Pharmacogenomics 9: 105-127, 2008.
29. Ozvegy C, Litman T, Szakacs G, Nagy Z, Bates S, Varadi A and Sarkadi B: Functional characterization of the human multidrug transporter, ABCG2, expressed in insect cells. Biochem Biophys Res Commun 285: 111-117, 2001. (Pubitemid 32912517)
30. Polgar O, Robey RW and Bates SE: ABCG2: structure, function and role in drug response. Expert Opin Drug Metab Toxicol 4: 1-15, 2008.
31. Dalton WS and Scheper RJ: Lung resistance-related protein: determining its role in multidrug resistance. J Natl Cancer Inst 91: 1604-1605, 1999. (Pubitemid 29479928)
32. Scheffer GL, Wijngaard PL, Flens MJ, Izquierdo MA, Slovak ML, Pinedo HM, Meijer CJ, Clevers HC and Scheper RJ: The drug resistance-related protein LRP is the human major vault protein. Nat Med 1: 578-582, 1995.
33. Scheffer GL, Schroeijers AB, Izquierdo MA, Wiemer EA and Scheper RJ: Lung resistance-related protein/major vault protein and vaults in multidrug-resistant cancer. Curr Opin Oncol 12: 550-556, 2000. (Pubitemid 32039654)
34. Izquierdo MA, van der Zee AG, Vermorken JB, van der Valk P, Belien JA, Giaccone G, Scheffer GL, Flens MJ, Pinedo HM, Kenemans P, Chris JLM Meijer, Elisabeth G. E.de Vriesand and Rik J. Scheper: Drug resistance-associated marker LRP for prediction of response to chemotherapy and prognoses in advanced ovarian carcinoma. J Natl Cancer Inst 87: 1230-1237, 1995.
35. List AF, Spier CS, Grogan TM, Johnson C, Roe DJ, Greer JP, Wolff SN, Broxterman HJ, Scheffer GL, Scheper RJ and Dalton WS: Overexpression of the major vault transporter protein lung-resistance protein predicts treatment outcome in acute myeloid leukemia. Blood 87: 2464-2469, 1996. (Pubitemid 26086891)
36. Talalay P: Chemoprotection against cancer by induction of phase 2 enzymes. Biofactors 12: 5-11, 2000.
37. McFadyen MC, McLeod HL, Jackson FC, Melvin WT, Doehmer J and Murray GI: Cytochrome P450 CYP1B1 protein expression: a novel mechanism of anticancer drug resistance. Biochem Pharmacol 62: 207-212, 2001. (Pubitemid 32522940)
38. Kivisto KT, Kroemer HK and Eichelbaum M: The role of human cytochrome P450 enzymes in the metabolism of anticancer agents: implications for drug interactions. Br J Clin Pharmacol 40: 523-530, 1995. (Pubitemid 26005556)
39. Kivisto KT, Bookjans G, Fromm MF, Griese EU, Munzel P and Kroemer HK: Expression of CYP3A4, CYP3A5 and CYP3A7 in human duodenal tissue. Br J Clin Pharmacol 42: 387-389, 1996. (Pubitemid 26284429)
40. Harris AL and Hochhauser D: Mechanisms of multidrug resistance in cancer treatment. Acta Oncol 31: 205-213, 1992.
41. Hayes JD and Pulford DJ: The glutathione S-transferase supergene family: regulation of GST and the contribution of the isoenzymes to cancer chemoprotection and drug resistance. Crit Rev Biochem Mol Biol 30: 445-600, 1995.
42. Schecter RL, Alaoui-Jamali MA and Batist G: Glutathione Stransferase in chemotherapy resistance and in carcinogenesis. Biochem Cell Biol 70: 349-353, 1992.
43. Rassool FV and Tomkinson AE: Targeting abnormal DNA double-strand break repair in cancer. Cell Mol Life Sci 67: 3699-3710.
44. Fojo T: Cancer, DNA repair mechanisms, and resistance to chemotherapy. J Natl Cancer Inst 93: 1434-1436, 2001.
45. Braastad CD, Leguia M and Hendrickson EA: Ku86 autoantigen related protein-1 transcription initiates from a CpG island and is induced by p53 through a nearby p53 response element. Nucleic Acids Res 30: 1713-1724, 2002. (Pubitemid 34679748)
46. Lavin MF: Ataxia-telangiectasia: from a rare disorder to a paradigm for cell signalling and cancer. Nat Rev Mol Cell Biol 9: 759-769, 2008.
47. Rajewsky N, Socci ND, Zapotocky M and Siggia ED: The evolution of DNA regulatory regions for proteo-gamma bacteria by interspecies comparisons. Genome Res 12: 298-308, 2002. (Pubitemid 34162996)
48. Sakamaki K and Satou Y: Caspases: evolutionary aspects of their functions in vertebrates. J Fish Biol 74: 727-753, 2009.
49. Bratton SB and Cohen GM: Death receptors leave a caspase footprint that Smacs of XIAP. Cell Death Differ 10: 4-6, 2003. (Pubitemid 36511824)
50. Safa AR and Pollok KE: Targeting the anti-apoptotic protein c-FLIP for cancer therapy. Cancers (Basel) 3: 1639-1671, 2011.
51. Fulda S and Debatin KM: Targeting inhibitor of apoptosis proteins (IAPs) for diagnosis and treatment of human diseases. Recent Pat Anticancer Drug Discov 1: 81-89, 2006.
52. Tepper CG and Seldin MF: Modulation of caspase-8 and FLICE-inhibitory protein expression as a potential mechanism of Epstein-Barr virus tumorigenesis in Burkitt's lymphoma. Blood 94: 1727-1737, 1999. (Pubitemid 29411323)
53. Herr I and Debatin KM: Cellular stress response and apoptosis in cancer therapy. Blood 98: 2603-2614, 2001.
54. Rosen D, Li JH, Keidar S, Markon I, Orda R and Berke G: Tumor immunity in perforin-deficient mice: a role for CD95 (Fas/Apo-1). J Immunol 164: 3229-3235, 2000. (Pubitemid 30148986)
55. Takeda K, Smyth MJ, Cretney E, Hayakawa Y, Yamaguchi N, Yagita H and Okumura K: Involvement of tumor necrosis factor-related apoptosis-inducing ligand in NK cell-mediated and IFN-gamma-dependent suppression of subcutaneous tumor growth. Cell Immunol 214: 194-200, 2001. (Pubitemid 34499473)
56. Nicholson DW and Thornberry NA: Apoptosis. Life and death decisions. Science 299: 214-215, 2003.
57. Lowe SW and Lin AW: Apoptosis in cancer. Carcinogenesis 21: 485-495, 2000. (Pubitemid 30137934)
58. Bartke T, Siegmund D, Peters N, Reichwein M, Henkler F, Scheurich P and Wajant H: p53 up-regulates cFLIP, inhibits transcription of NF-kappaB-regulated genes and induces caspase-8-independent cell death in DLD-1 cells. Oncogene 20: 571-580, 2001. (Pubitemid 32156181)
59. Hoffman WH, Biade S, Zilfou JT, Chen J and Murphy M: Transcriptional repression of the anti-apoptotic survivin gene by wild type p53. J Biol Chem 277: 3247-3257, 2002. (Pubitemid 34953189)
60. Hwang PH, Yi HK, Kim DS, Nam SY, Kim JS and Lee DY: Suppression of tumorigenicity and metastasis in B16F10 cells by PTEN/MMAC1/TEP1 gene. Cancer Lett 172: 83-91, 2001. (Pubitemid 32823476)
61. Moroni MC, Hickman ES, Lazzerini Denchi E, Caprara G, Colli E, Cecconi F, Muller H and Helin K: APAF-1 is a transcriptional target for E2F and p53. Nat Cell Biol 3: 552-558, 2001. (Pubitemid 32536851)
62. Ryan KM, Phillips AC and Vousden KH: Regulation and function of the p53 tumor suppressor protein. Curr Opin Cell Biol 13: 332-337, 2001. (Pubitemid 32429498)
63. Gasco M, Shami S and Crook T: The p53 pathway in breast cancer. Breast Cancer Res 4: 70-76, 2002. (Pubitemid 34248123)
64. Schmitt CA, McCurrach ME, de Stanchina E, Wallace-Brodeur RR and Lowe SW: INK4a/ARF mutations accelerate lymphomagenesis and promote chemoresistance by disabling p53. Genes Dev 13: 2670-2677, 1999. (Pubitemid 29508554)
65. Igney FH and Krammer PH: Death and anti-death: tumour resistance to apoptosis. Nat Rev Cancer 2: 277-288, 2002. (Pubitemid 37328781)
66. Youle RJ and Strasser A: The BCL-2 protein family: opposing activities that mediate cell death. Nat Rev Mol Cell Biol 9: 47-59, 2008.
67. Huang WC and Hung MC: Induction of AKT activity by chemotherapy confers acquired resistance. J Formos Med Assoc 108: 180-194, 2009.
68. Steelman LS, Navolanic P, Chappell WH, Abrams SL, Wong EW, Martelli AM, Cocco L, Stivala F, Libra M, Nicoletti F, Drobot LB, Franklin RA and McCubrey JA: Involvement of AKT and mTOR in chemotherapeutic- and hormonal-based drug resistance and response to radiation in breast cancer cells. Cell Cycle 10: 3003-3015.
69. Iida K, Nakayama K, Rahman MT, Rahman M, Ishikawa M, Katagiri A, Yeasmin S, Otsuki Y, Kobayashi H, Nakayama S and Miyazaki K: EGFR gene amplification is related to adverse clinical outcomes in cervical squamous cell carcinoma, making the EGFR pathway a novel therapeutic target. Br J Cancer 105: 420-427.
70. Choy G, Liu JW, Chandra D and Tang DG: Cell survival signaling during apoptosis: implications in drug resistance and anticancer therapeutic development. Prog Drug Res 63: 115-145, 2005. (Pubitemid 41406432)
71. Sordet O, Khan QA, Kohn KW and Pommier Y: Apoptosis induced by topoisomerase inhibitors. Curr Med Chem Anticancer Agents 3: 271-290, 2003. (Pubitemid 36758302)
72. Tang D, Okada H, Ruland J, Liu L, Stambolic V, Mak TW and Ingram AJ: Akt is activated in response to an apoptotic signal. J Biol Chem 276: 30461-30466, 2001.
73. Karpinich NO, Tafani M, Rothman RJ, Russo MA and Farber JL: The course of etoposide-induced apoptosis from damage to DNA and p53 activation to mitochondrial release of cytochrome c. J Biol Chem 277: 16547-16552, 2002. (Pubitemid 34967670)
74. Wu H, Goel V and Haluska FG: PTEN signaling pathways in melanoma. Oncogene 22: 3113-3122, 2003. (Pubitemid 36713763)
75. Huang H, Cheville JC, Pan Y, Roche PC, Schmidt LJ and Tindall DJ: PTEN induces chemosensitivity in PTEN-mutated prostate cancer cells by suppression of BCL-2 expression. J Biol Chem 276: 38830-38836, 2001.
76. Yuan XJ and Whang YE: PTEN sensitizes prostate cancer cells to death receptor-mediated and drug-induced apoptosis through a FADD-dependent pathway. Oncogene 21: 319-327, 2002.
77. Karin M and Ben-Neriah Y: Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity. Annu Rev Immunol 18: 621-663, 2000. (Pubitemid 30365393)
78. Zhou G and Kuo MT: NF-kappaB-mediated induction of mdr1b expression by insulin in rat hepatoma cells. J Biol Chem 272: 15174-15183, 1997. (Pubitemid 27255533)
79. Antonsson B: Bax and other pro-apoptotic Bcl-2 family killer proteins and their victim the mitochondrion. Cell Tissue Res 306: 347-361, 2001.
80. Nakashio A, Fujita N, Rokudai S, Sato S and Tsuruo T: Prevention of phosphatidylinositol 3′-kinase-Akt survival signaling pathway during topotecan-induced apoptosis. Cancer Res 60: 5303-5309, 2000.
81. Markovina S, Callander NS, O'Connor SL, Kim J, Werndli JE, Raschko M, Leith CP, Kahl BS, Kim K and Miyamoto S: Bortezomib-resistant nuclear factor-kappaB activity in multiple myeloma cells. Mol Cancer Res 6: 1356-1364, 2008.
82. Peng H, Wen J, Li H, Chang J and Zhou X: Drug inhibition profile prediction for NFκB pathway in multiple myeloma. PLoS One 6: e14750.
83. Cortes Sempere M, Rodriguez Fanjul V, Sanchez Perez I and Perona R: The role of the NFkappaB signalling pathway in cancer. Clin Transl Oncol 10: 143-147, 2008.
84. Cataldi A, Rapino M, Centurione L, Sabatini N, Grifone G, Garaci F and Rana R: NFκB activation plays an anti-apoptotic role in human leukemic K562 cells exposed to ionizing radiation. J Cell Biochem 89: 956-963, 2003. (Pubitemid 36927727)
85. Wang CY, Cusack JC Jr., Liu R and Baldwin AS Jr.: Control of inducible chemoresistance: enhanced antitumor therapy through increased apoptosis by inhibition of NF-kappaB. Nat Med 5: 412-417, 1999. (Pubitemid 29180579)
86. Jones DR, Broad RM, Madrid LV, Baldwin AS Jr. and Mayo MW: Inhibition of NF-kappaB sensitizes non-small cell lung cancer cells to chemotherapy-induced apoptosis. Ann Thorac Surg 70: 930-936; discussion 936-937, 2000.
87. Ling MT, Wang X, Ouyang XS, Xu K, Tsao SW and Wong YC: Id-1 expression promotes cell survival through activation of NF-kappaB signalling pathway in prostate cancer cells. Oncogene 22: 4498-4508, 2003. (Pubitemid 36920693)
88. Muerkoster S, Arlt A, Witt M, Gehrz A, Haye S, March C, Grohmann F, Wegehenkel K, Kalthoff H, Folsch UR and Schafer H: Usage of the NF-kappaB inhibitor sulfasalazine as sensitizing agent in combined chemotherapy of pancreatic cancer. Int J Cancer 104: 469-476, 2003. (Pubitemid 36323918)
89. Surh YJ: Cancer chemoprevention with dietary phytochemicals. Nat Rev Cancer 3: 768-780, 2003.
90. Wargovich MJ: Nutrition and cancer: the herbal revolution. Curr Opin Gastroenterol 15: 177-180, 1999.
91. Aggarwal BB and Shishodia S: Molecular targets of dietary agents for prevention and therapy of cancer. Biochem Pharmacol 71: 1397-1421, 2006.
92. Shim JH, Su ZY, Chae JI, Kim DJ, Zhu F, Ma WY, Bode AM, Yang CS and Dong Z: Epigallocatechin gallate suppresses lung cancer cell growth through RAS-GTPase-activating protein SH3 domain-binding protein 1. Cancer Prev Res (Phila) 3: 670-679, 2010.
93. Luo T, Wang J, Yin Y, Hua H, Jing J, Sun X, Li M, Zhang Y and Jiang Y: (-)-Epigallocatechin gallate sensitizes breast cancer cells to paclitaxel in a murine model of breast carcinoma. Breast Cancer Res 12: R8, 2010.
94. Lahiry L, Saha B, Chakraborty J, Adhikary A, Mohanty S, Hossain DM, Banerjee S, Das K, Sa G and Das T: Theaflavins target FAS/caspase-8 and AKT/pBAD pathways to induce apoptosis in p53-mutated human breast cancer cells. Carcinogenesis 31: 259-268 2010.
95. Lahiry L, Saha B, Chakraborty J, Bhattacharyya S, Chattopadhyay S, Banerjee S, Choudhuri T, Mandal D, Bhattacharyya A, Sa G and Das T: Contribution of p53-mediated Bax transactivation in theaflavin-induced mammary epithelial carcinoma cell apoptosis. Apoptosis 13: 771-781, 2008.
96. Adhikary A, Mohanty S, Lahiry L, Hossain DM, Chakraborty S and Das T: Theaflavins retard human breast cancer cell migration by inhibiting NF-kappaB via p53-ROS cross-talk. FEBS Lett 584: 7-14, 2010.
97. Chattopadhyay S, Bhattacharyya S, Saha B, Chakraborty J, Mohanty S, Sakib Hossain DM, Banerjee S, Das K, Sa G and Das T: Tumor-shed PGE(2) impairs IL2Rγ-signaling to inhibit CD4 T cell survival: regulation by theaflavins. PLoS One 4: e7382, 2009.
98. Bhattacharyya A, Choudhuri T, Pal S, Chattopadhyay S, G KD, Sa G and Das T: Apoptogenic effects of black tea on Ehrlich's ascites carcinoma cell. Carcinogenesis 24: 75-80, 2003. (Pubitemid 36193197)
99. Bhattacharyya S, Mandal D, Saha B, Sen GS, Das T and Sa G: Curcumin prevents tumor-induced T cell apoptosis through Stat-5a-mediated Bcl-2 induction. J Biol Chem 282: 15954-15964, 2007. (Pubitemid 47100378)
100. Brown KC, Witte TR, Hardman WE, Luo H, Chen YC, Carpenter AB, Lau JK and Dasgupta P: Capsaicin displays antiproliferative activity against human small cell lung cancer in cell culture and nude mice models via the E2F pathway. PLoS One 5: e10243.
101. Huang SP, Chen JC, Wu CC, Chen CT, Tang NY, Ho YT, Lo C, Lin JP, Chung JG and Lin JG: Capsaicin-induced apoptosis in human hepatoma HepG2 cells. Anticancer Res 29: 165-174, 2009.
102. Cheah YH, Nordin FJ, Sarip R, Tee TT, Azimahtol HL, Sirat HM, Rashid BA, Abdullah NR and Ismail Z: Combined xanthorrhizol-curcumin exhibits synergistic growth inhibitory activity via apoptosis induction in human breast cancer cells MDA-MB-231. Cancer Cell Int 9: 1, 2009.
103. Siddiqui IA, Malik A, Adhami VM, Asim M, Hafeez BB, Sarfaraz S and Mukhtar H: Green tea polyphenol EGCG sensitizes human prostate carcinoma LNCaP cells to TRAIL-mediated apoptosis and synergistically inhibits biomarkers associated with angiogenesis and metastasis. Oncogene 27: 2055-2063, 2008. (Pubitemid 351442738)
104. Pal S, Bhattacharyya S, Choudhuri T, Datta GK, Das T and Sa G: Amelioration of immune cell number depletion and potentiation of depressed detoxification system of tumor-bearing mice by curcumin. Cancer Detect Prev 29: 470-478, 2005. (Pubitemid 41406143)
105. Pal S, Choudhuri T, Chattopadhyay S, Bhattacharya A, Datta GK, Das T and Sa G: Mechanisms of curcumin-induced apoptosis of Ehrlich's ascites carcinoma cells. Biochem Biophys Res Commun 288: 658-665, 2001. (Pubitemid 33030080)
106. Chakraborty J, Banerjee S, Ray P, Hossain DM, Bhattacharyya S, Adhikary A, Chattopadhyay S, Das T and Sa G: Gain of cellular adaptation due to prolonged p53 impairment leads to functional switchover from p53 to p73 during DNA damage in acute myeloid leukemia cells. J Biol Chem 285: 33104-33112, 2010.
107. Choudhuri T, Pal S, Das T and Sa G: Curcumin selectively induces apoptosis in deregulated cyclin D1-expressed cells at G2 phase of cell cycle in a p53-dependent manner. J Biol Chem 280: 20059-20068, 2005. (Pubitemid 41379535)
108. Choudhuri T, Pal S, Agwarwal ML, Das T and Sa G: Curcumin induces apoptosis in human breast cancer cells through p53-dependent BAX induction. FEBS Lett 512: 334-340, 2002. (Pubitemid 34164505)
109. Bhattacharyya S, Mandal D, Sen GS, Pal S, Banerjee S, Lahiry L, Finke JH, Tannenbaum CS, Das T and Sa G: Tumor-induced oxidative stress perturbs nuclear factor-kappaB activity-augmenting tumor necrosis factor-alpha-mediated T-cell death: protection by curcumin. Cancer Res 67: 362-370, 2007. (Pubitemid 46142796)
110. Bhattacharyya S, Md Sakib Hossain D, Mohanty S, Sankar Sen G, Chattopadhyay S, Banerjee S, Chakraborty J, Das K, Sarkar D, Das T and Sa G: Curcumin reverses T-cell-mediated adaptive immune dysfunctions in tumor-bearing hosts. Cell Mol Immunol 7: 306-315, 2010.
111. Strimpakos AS and Sharma RA: Curcumin: preventive and therapeutic properties in laboratory studies and clinical trials. Antioxid Redox Signal 10: 511-545, 2008.
112. Das T, Sa G, Saha B and Das K: Multifocal signal modulation therapy of cancer: ancient weapon, modern targets. Mol Cell Biochem 336: 85-95, 2010.
113. Aggarwal BB, Sundaram C, Malani N and Ichikawa H: Curcumin: the Indian solid gold. Adv Exp Med Biol 595: 1-75, 2007.
114. Anand P, Sundaram C, Jhurani S, Kunnumakkara AB and Aggarwal BB: Curcumin and cancer: an old-age disease with an age-old solution. Cancer Lett 267: 133-164, 2008.
115. Jagetia GC and Aggarwal BB: Spicing up of the immune system by curcumin. J Clin Immunol 27: 19-35, 2007.
116. Kuttan G, Kumar KB, Guruvayoorappan C and Kuttan R: Antitumor, anti-invasion, and antimetastatic effects of curcumin. Adv Exp Med Biol 595: 173-184, 2007.
117. Ramachandran C, Rodriguez S, Ramachandran R, Raveendran Nair PK, Fonseca H, Khatib Z, Escalon E and Melnick SJ: Expression profiles of apoptotic genes induced by curcumin in human breast cancer and mammary epithelial cell lines. Anticancer Res 25: 3293-3302, 2005. (Pubitemid 41105203)
118. Dhillon N, Aggarwal BB, Newman RA, Wolff RA, Kunnumakkara AB, Abbruzzese JL, Ng CS, Badmaev V and Kurzrock R: Phase II trial of curcumin in patients with advanced pancreatic cancer. Clin Cancer Res 14: 4491-4499, 2008.
119. Aggarwal BB, Kumar A and Bharti AC: Anticancer potential of curcumin: preclinical and clinical studies. Anticancer Res 23: 363-398, 2003. (Pubitemid 36361976)
120. Cheng AL, Hsu CH, Lin JK, Hsu MM, Ho YF, Shen TS, Ko JY, Lin JT, Lin BR, Ming-Shiang W, Yu HS, Jee SH, Chen GS, Chen TM, Chen CA, Lai MK, Pu YS, Pan MH, Wang YJ, Tsai CC and Hsieh CY: Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res 21: 2895-2900, 2001. (Pubitemid 33051148)
121. Sharma SK, George N, Kadhiravan T, Saha PK, Mishra HK and Hanif M: Prevalence of extensively drug-resistant tuberculosis among patients with multidrug-resistant tuberculosis: a retrospective hospital-based study. Indian J Med Res 130: 392-395, 2009.
122. Anuchapreeda S, Leechanachai P, Smith MM, Ambudkar SV and Limtrakul PN: Modulation of P-glycoprotein expression and function by curcumin in multidrug-resistant human KB cells. Biochem Pharmacol 64: 573-582, 2002.
123. Chearwae W, Shukla S, Limtrakul P and Ambudkar SV: Modulation of the function of the multidrug resistance-linked ATP-binding cassette transporter ABCG2 by the cancer chemopreventive agent curcumin. Mol Cancer Ther 5: 1995-2006, 2006. (Pubitemid 44336571)
124. Chearwae W, Wu CP, Chu HY, Lee TR, Ambudkar SV and Limtrakul P: Curcuminoids purified from turmeric powder modulate the function of human multidrug-resistance protein 1 (ABCC1). Cancer Chemother Pharmacol 57: 376-388, 2006.
125. Sharma M, Manoharlal R, Shukla S, Puri N, Prasad T, Ambudkar SV and Prasad R: Curcumin modulates efflux mediated by yeast ABC multidrug transporters and is synergistic with antifungals. Antimicrob Agents Chemother 53: 3256-3265, 2009.
126. Chearwae W, Anuchapreeda S, Nandigama K, Ambudkar SV and Limtrakul P: Biochemical mechanism of modulation of human P-glycoprotein (ABCB1) by curcumin I, II, and III purified from Turmeric powder. Biochem Pharmacol 68: 2043-2052, 2004. (Pubitemid 39346194)
127. Limtrakul P, Anuchapreeda S and Buddhasukh D: Modulation of human multidrug-resistance MDR-1 gene by natural curcuminoids. BMC Cancer 4: 13, 2004.
128. Khar A, Ali AM, Pardhasaradhi BV, Varalakshmi CH, Anjum R and Kumari AL: Induction of stress response renders human tumor cell lines resistant to curcumin-mediated apoptosis: role of reactive oxygen intermediates. Cell Stress Chaperones 6: 368-376, 2001. (Pubitemid 33123490)
129. M Khopde S, Priyadarsini KI, Venkatesan P and Rao MN: Free radical scavenging ability and antioxidant efficiency of curcumin and its substituted analogue. Biophys Chem 80: 85-91, 1999.
130. Mori Y, Tatematsu K, Koide A, Sugie S, Tanaka T and Mori H: Modification by curcumin of mutagenic activation of carcinogenic N-nitrosamines by extrahepatic cytochromes P-450 2B1 and 2E1 in rats. Cancer Sci 97: 896-904, 2006. (Pubitemid 44151271)
131. Liu A, Yoshioka K, Salerno V and Hsieh P: The mismatch repair-mediated cell cycle checkpoint response to fluorodeoxyuridine. J Cell Biochem 105: 245-254, 2008.
132. Rowe DL, Ozbay T, O'Regan RM and Nahta R: Modulation of the BRCA1 protein and induction of apoptosis in triple-negative breast cancer cell lines by the polyphenolic compound curcumin. Breast Cancer (Auckl) 3: 61-75, 2009.
133. Lu HF, Yang JS, Lai KC, Hsu SC, Hsueh SC, Chen YL, Chiang JH, Lu CC, Lo C, Yang MD and Chung JG: Curcumin-induced DNA damage and inhibited DNA repair genes expressions in mouse-rat hybrid retina ganglion cells (N18). Neurochem Res 34: 1491-1497, 2009.
134. Lu HF, Lai KC, Hsu SC, Lin HJ, Yang MD, Chen YL, Fan MJ, Yang JS, Cheng PY, Kuo CL and Chung JG: Curcumin induces apoptosis through FAS and FADD, in caspase-3-dependent and -independent pathways in the N18 mouse-rat hybrid retina ganglion cells. Oncol Rep 22: 97-104, 2009.
135. Xiao H and Zhang KJ: Antiproliferative effect of curcumin combined with cyclophosmide on the growth of human lymphoma cell line HT/CTX with drug resistance and its relation with FA/BRCA pathway. Zhongguo Shi Yan Xue Ye Xue Za Zhi 16: 804-808, 2008 (in Chinese).
136. Dhandapani KM, Mahesh VB and Brann DW: Curcumin suppresses growth and chemoresistance of human glioblastoma cells via AP-1 and NF κB transcription factors. J Neurochem 102: 522-538, 2007. (Pubitemid 47000605)
137. Wahl H, Tan L, Griffith K, Choi M and Liu JR: Curcumin enhances APO2L/TRAIL-induced apoptosis in chemoresistant ovarian cancer cells. Gynecol Oncol 105: 104-112, 2007. (Pubitemid 46442871)
138. Deeb D, Xu YX, Jiang H, Gao X, Janakiraman N, Chapman RA and Gautam SC: Curcumin (diferuloyl-methane) enhances tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in LNCaP prostate cancer cells. Mol Cancer Ther 2: 95-103, 2003.
139. Deeb DD, Jiang H, Gao X, Divine G, Dulchavsky SA and Gautam SC: Chemosensitization of hormone-refractory prostate cancer cells by curcumin to TRAIL-induced apoptosis. J Exp Ther Oncol 5: 81-91, 2005. (Pubitemid 41739368)
140. Deeb D, Jiang H, Gao X, Al-Holou S, Danyluk AL, Dulchavsky SA and Gautam SC: Curcumin [1,7-bis (4-hydroxy-3- methoxyphenyl)-1-6-heptadine-3,5-dione; C21H20O6] sensitizes human prostate cancer cells to tumor necrosis factor-related apoptosis-inducing ligand/APO2L-induced apoptosis by suppressing nuclear factor-kappaB via inhibition of the prosurvival AKT signaling pathway. J Pharmacol Exp Ther 321: 616-625, 2007. (Pubitemid 46624498)
141. Gao X, Deeb D, Jiang H, Liu YB, Dulchavsky SA and Gautam SC: Curcumin differentially sensitizes malignant glioma cells to TRAIL/Apo2L-mediated apoptosis through activation of procaspases and release of cytochrome c from mitochondria. J Exp Ther Oncol 5: 39-48, 2005. (Pubitemid 41076989)
142. Shankar S, Ganapathy S, Chen Q and Srivastava RK: Curcumin sensitizes TRAIL-resistant xenografts: molecular mechanisms of apoptosis, metastasis and angiogenesis. Mol Cancer 7: 16, 2008.
143. Woo JH, Kim YH, Choi YJ, Kim DG, Lee KS, Bae JH, Min DS, Chang JS, Jeong YJ, Lee YH, Park JW and Kwon TK: Molecular mechanisms of curcumin-induced cytotoxicity: induction of apoptosis through generation of reactive oxygen species, downregulation of BCL-XL and IAP, the release of cytochrome c and inhibition of Akt. Carcinogenesis 24: 1199-1208, 2003. (Pubitemid 36927060)
144. Kulik GI: Comparative in vitro study of the effects of the new antitumor drug Ukrain and several cytostatic agents on the thiol groups in the tissue of Guerin carcinoma and its resistance to cisplatin variant. Drugs Exp Clin Res 24: 277-280, 1998.
145. Aggarwal S, Ichikawa H, Takada Y, Sandur SK, Shishodia S and Aggarwal BB: Curcumin (diferuloylmethane) down-regulates expression of cell proliferation and antiapoptotic and metastatic gene products through suppression of IκBα kinase and AKT activation. Mol Pharmacol 69: 195-206, 2006. (Pubitemid 43048906)
146. Patel BB, Gupta D, Elliott AA, Sengupta V, Yu Y and Majumdar AP: Curcumin targets FOLFOX-surviving colon cancer cells via inhibition of EGFRs and IGF-1R. Anticancer Res 30: 319-325, 2010.
147. Madonna G, Dansky Ullman C, Gentilcore G, Palmieri G and Ascierto PA: NFκB as potential target in the treatment of melanoma. J Transl Med 10: 53, 2012.
148. Divya CS and Pillai MR: Antitumor action of curcumin in human papillomavirus associated cells involves down-regulation of viral oncogenes, prevention of NFκB and AP-1 translocation, and modulation of apoptosis. Mol Carcinog 45: 320-332, 2006.
149. Duvoix A, Blasius R, Delhalle S, Schnekenburger M, Morceau F, Henry E, Dicato M and Diederich M: Chemopreventive and therapeutic effects of curcumin. Cancer Lett 223: 181-190, 2005. (Pubitemid 40719616)
150. Mimeault M and Batra SK: Potential applications of curcumin and its novel synthetic analogs and nanotechnology-based formulations in cancer prevention and therapy. Chin Med 6: 31, 2011.
151. Sung B, Kunnumakkara AB, Sethi G, Anand P, Guha S and Aggarwal BB: Curcumin circumvents chemoresistance in vitro and potentiates the effect of thalidomide and bortezomib against human multiple myeloma in nude mouse model. Mol Cancer Ther 8: 959-970, 2009.
152. Yallapu MM, Maher DM, Sundram V, Bell MC, Jaggi M and Chauhan SC: Curcumin induces chemo/radio-sensitization in ovarian cancer cells and curcumin nanoparticles inhibit ovarian cancer cell growth. J Ovarian Res 3: 11, 2010.
153. Ilbey YO, Ozbek E, Cekmen M, Simsek A, Otunctemur A and Somay A: Protective effect of curcumin in cisplatin-induced oxidative injury in rat testis: mitogen-activated protein kinase and nuclear factor-kappa B signaling
154. Kim DS, Park SS, Nam BH, Kim IH and Kim SY: Reversal of drug resistance in breast cancer cells by transglutaminase 2 inhibition and nuclear factor-kappaB inactivation. Cancer Res 66: 10936-10943, 2006.
155. Schneider G, Henrich A, Greiner G, Wolf V, Lovas A, Wieczorek M, Wagner T, Reichardt S, von Werder A, Schmid RM, Weih F, Heinzel T, Saur D and Kramer OH: Cross talk between stimulated NF-kappaB and the tumor suppressor p53. Oncogene 29: 2795-806, 2010.
156. Sen GS, Mohanty S, Hossain DM, Bhattacharyya S, Banerjee S, Chakraborty J, Saha S, Ray P, Bhattacharjee P, Mandal D, Bhattacharya A, Chattopadhyay S, Das T and Sa G: Curcumin enhances the efficacy of chemotherapy by tailoring p65NFkappaB-p300 cross-talk in favor of p53-p300 in breast cancer. J Biol Chem 286: 42232-42247, 2011.
157. Wang JC and Dick JE: Cancer stem cells: lessons from leukemia. Trends Cell Biol 15: 494-501, 2005. (Pubitemid 41253469)
158. Ailles LE and Weissman IL: Cancer stem cells in solid tumors. Curr Opin Biotechnol 18: 460-466, 2007. (Pubitemid 350116595)
159. Dean M, Fojo T and Bates S: Tumour stem cells and drug resistance. Nat Rev Cancer 5: 275-284, 2005. (Pubitemid 40488633)
160. Nautiyal J, Kanwar SS, Yu Y and Majumdar AP: Combination of dasatinib and curcumin eliminates chemoresistant colon cancer cells. J Mol Signal 6: 7, 2011.
161. Lin L, Fuchs J, Li C, Olson V, Bekaii-Saab T and Lin J: STAT3 signaling pathway is necessary for cell survival and tumorsphere forming capacity in ALDH/CD133 stem cell-like human colon cancer cells. Biochem Biophys Res Commun 416: 246-251, 2011.
162. Fong D, Yeh A, Naftalovich R, Choi TH and Chan MM: Curcumin inhibits the side population (SP) phenotype of the rat C6 glioma cell line: towards targeting of cancer stem cells with phytochemicals. Cancer Lett 293: 65-72, 2010.
163. Kakarala M, Brenner DE, Korkaya H, Cheng C, Tazi K, Ginestier C, Liu S, Dontu G and Wicha MS: Targeting breast stem cells with the cancer preventive compounds curcumin and piperine. Breast Cancer Res Treat 122: 777-785, 2010.